Huygens, Simone A. http://orcid.org/0000-0003-0669-4149
Versteegh, Matthijs M.
Vegter, Stefan
Schouten, L. Jan
Kanters, Tim A.
Funding for this research was provided by:
Novartis Pharma
Article History
Accepted: 23 January 2021
First Online: 19 February 2021
Declarations
:
: Simone Huygens, Matthijs Versteegh and Tim Kanters are employees of iMTA, which was sponsored by Novartis Pharma B.V. to independently review and alter the global cost-effectiveness model for voretigene neparvovec for RPE65-mediated inherited retinal disease to the national setting.
: Simone Huygens, Matthijs Versteegh and Tim Kanters are employees of iMTA, which was sponsored by Novartis Pharma B.V. to review and alter the global cost-effectiveness model for voretigene neparvovec for RPE65-mediated inherited retinal disease to the national setting. The sponsor contract contains a clause guaranteeing independent decisions to uphold the scientific quality and integrity of the study and the manuscript, including freedom to publish irrespective of the outcomes of the study. Stefan Vegter is an employee of Novartis Pharma B.V. Jan Schouten did not have any conflict of interest.
: Not applicable.
: Not applicable.
: Not applicable.
: The manuscripts of the economic evaluations that were reviewed in this manuscript are publicly available in the published literature (see references). The technical report of the Dutch health economic model is available from the corresponding author upon request.
: The codes of the underlying health economic models used in the economic evaluations that were reviewed in this manuscript are not publicly available.
: Simone Huygens, Tim Kanters, Matthijs Versteegh and Stefan Vegter contributed to the study conception and design. Data analyses using the Dutch health economic model were performed by Simone Huygens. The first draft of the manuscript was written by Simone Huygens and all authors commented on subsequent versions of the manuscript. All authors read and approved the final manuscript.